Chester County News and Community Website
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (NASDAQ: APRE) will present updated interim results from its Phase 1 trial of WEE1 inhibitor APR-1051 in November, providing a new clinical readout from …
Aprea to Present Updated APR-1051 Cancer Trial Data Read More DOYLESTOWN, PA — Aprea Therapeutics Inc. (Nasdaq: APRE) will put its clinical-stage cancer drug pipeline before investors at the H.C. Wainwright Global Investment Conference Sept. 14-16 as the company advances …
Aprea Puts Cancer Drug Pipeline Before Investors Read More DOYLESTOWN, PA — Aprea Therapeutics Inc. (Nasdaq: APRE) is building patent protection around its two precision-oncology programs that could extend into the 2040s, reinforcing the intellectual-property position behind drug candidates …
Aprea Extends Patent Reach Around Oncology Drug Pipeline Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (NASDAQ: APRE) is expanding its Phase 1 trial of experimental cancer drug APR-1051 after reporting early signs of antitumor activity, using proceeds from a …
Aprea Expands Cancer Trial as APR-1051 Shows Early Activity Read More DOYLESTOWN, PA — Aprea Therapeutics Inc. (Nasdaq: APRE) is expanding enrollment and broadening the clinical development strategy for its investigational WEE1 inhibitor APR-1051 as the company advances a Phase 1 …
Aprea Expands APR-1051 Trial as Enrollment Accelerates Read More DOYLESTOWN, PA — Aprea Therapeutics reported early signs of anti-tumor activity from its ongoing Phase 1 trial of experimental cancer therapy APR-1051, with partial responses observed in patients with advanced …
Aprea Reports Early Tumor Responses in Phase 1 APR-1051 Study Read More DOYLESTOWN, PA — Aprea Therapeutics (Nasdaq: APRE) is expanding enrollment in a Phase 1 study of its experimental cancer drug APR-1051 after early clinical data showed tumor responses and disease …
Aprea Expands Cancer Trial After Early Tumor Responses Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) said it will expand enrollment in its lead cancer drug trial after closing an oversubscribed $30 million private placement, as early patient …
Aprea Expands Cancer Trial After $30 Million Financing Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) will present early results from a Phase 1 clinical trial of its WEE1 inhibitor APR-1051 at the 2026 American Society of Clinical …
Aprea Abstract Accepted for ASCO on APR-1051 Phase 1 Study Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported a confirmed partial response in its ongoing Phase 1 clinical trial evaluating APR-1051, a WEE1 kinase inhibitor, in patients with biomarker-defined …
Aprea Reports Partial Response in APR-1051 Cancer Trial Read More